Reactive astrogliosis has long been recognized as a ubiquitous feature of CNS pathologies. Although its roles in CNS pathology are only beginning to be defined, genetic tools are enabling molecular dissection of the functions and mechanisms of reactive astrogliosis in vivo. It is now clear that reactive astrogliosis is not simply an all-or-nothing phenomenon but, rather, is a finely gradated continuum of molecular, cellular, and functional changes that range from subtle alterations in gene expression to scar formation. These changes can exert both beneficial and detrimental effects in a context-dependent manner determined by specific molecular signaling cascades. Dysfunction of either astrocytes or the process of reactive astrogliosis is emerging as an important potential source of mechanisms that might contribute to, or play primary roles in, a host of CNS disorders via loss of normal or gain of abnormal astrocyte activities. A rapidly growing understanding of the mechanisms underlying astrocyte signaling and reactive astrogliosis has the potential to open doors to identifying many molecules that might serve as novel therapeutic targets for a wide range of neurological disorders. This review considers general principles and examines selected examples regarding the potential of targeting specific molecular aspects of reactive astrogliosis for therapeutic manipulations, including regulation of glutamate, reactive oxygen species, and cytokines.
INTRODUCTION
Astrocytes are specialized glial cells that are ubiquitous throughout all regions of the CNS. Astrocytes outnumber neurons by more than fivefold and contiguously tile the entire CNS in an essentially uninterrupted manner. Although neurons have long been the focus of attention as mediators of CNS functions, an ever-growing body of evidence indicates that astrocytes and other glia play primary roles in neural processing in both health and disease. Astrocytes play essential roles in normal, continually ongoing CNS functions, including regulation of blood flow, provision of energy metabolites to neurons, participation in synaptic function and plasticity, and maintenance of the extracellular balance of ions, fluid balance, and transmitters (as reviewed in detail elsewhere [1] [2] [3] [4] [5] ). In addition, astrocytes respond to all forms of CNS insult, such as infection, trauma, ischemia, and neurodegenerative disease, by a process commonly referred to as reactive astrogliosis, which involves changes in astrocyte molecular expression and in severe cases results in scar formation (reviewed in detail elsewhere 6, 7 ). Reactive astrogliosis is not merely a marker of neuropathology, but plays essential roles in orchestrating the injury response, as well as in regulating inflammation and repair in a manner that markedly affects functional and clinical outcomes. 5, 7, 8 Enormous progress has been made in characterizing molecular mechanisms underlying astrocyte and reactive astrocyte functions, and a vast molecular arsenal at the disposal of astrocytes and reactive astrocytes is being defined. Accordingly, astrocytes and reactive astrocytes are increasingly recognized as potential targets for novel therapeutic strategies for a variety of CNS conditions. 7,9 -11 Here we review recent findings and consider general principles regarding the potential of targeting reactive astrogliosis for therapeutic manipulations, with a focus on a number of specific molecular mechanisms as examples.
gliosis have long been dominated by the 100-year-old recognition that scars formed by reactive astrocytes inhibit axon regeneration and by the interpretation that this scar is the main impediment to functional recovery after CNS injury or disease. These observations have sometimes led to the simplistic notion that reactive astrogliosis is an all-or-nothing maladaptive process synonymous with scar formation and that the total inhibition of reactive astrogliosis could be regarded as a therapeutic strategy. This absolutely negative view of reactive astrogliosis is no longer tenable, and it is clear from a growing body of experimental evidence that there is a normal, adaptive process of reactive astrogliosis, including scar formation, which exerts essential beneficial functions. 5, 7, 8 These studies have shown that reactive astrogliosis is not a simple, all-or-nothing phenomenon, nor is it ubiquitously synonymous with scar formation. Instead, reactive astrogliosis is a finely gradated continuum of changes that occur in response to all CNS insults in a context-dependent manner regulated by specific signaling events. 7 In reactive astrogliosis, the continuum of changes ranges from reversible alterations in gene expression and cell hypertrophy with preservation of cellular domains and tissue structure after mild insults to long-lasting scar formation with permanent rearrangement of tissue structure after severe insults. 5, 7, 8 The changes effected during reactive astrogliosis have the potential to alter astrocyte activities through both gain and loss of functions that can affect surrounding neural and non-neural cells both beneficially and detrimentally. 5, 7, 8 Because astrocytes and reactive astrocytes have the potential to influence essentially all aspects of neural function through the regulation of blood flow and provision of energy substrates, or by influencing synaptic function and plasticity, it is perhaps not surprising that dysfunction of the processes underlying reactive astrogliosis and scar formation has the potential to contribute to, or even be the primary cause of, CNS disease mechanisms, either through loss of normal functions or through gain of detrimental effects. 5, 7 Numerous studies using transgenic and experimental animal models provide compelling evidence that reactive astrocytes protect CNS cells and tissue in multiple ways that involve a variety of different molecular mechanisms, including i) uptake of potentially excitotoxic glutamate, [12] [13] [14] ii) protection from oxidative stress via glutathione production, 14 -18 iii) neuroprotection via adenosine release, 19 iv) protection from NH 4 ϩ toxicity, 20 v) neuroprotection by degradation of amyloid-␤ peptides, 21 vi) facilitation of blood-brain barrier repair, 13 vii) reduction of vasogenic edema after trauma, stroke, or obstructive hydrocephalus, 13, 22 viii) stabilization of extracellular fluid and ion balance thereby increasing seizure threshold, 22 and ix) limiting the spread of inflammatory cells or infectious agents from areas of tissue damage or disease into healthy CNS parenchyma. 13, [23] [24] [25] [26] [27] [28] [29] Nevertheless, it is also clear that reactive astrocytes can also play harmful roles during injury or disease through gain of abnormal effects such as overproduction of reactive oxygen species (ROS) or certain inflammatory cytokines. 5, 7, 14 Thus, overall, reactive astrocytes have the potential to influence injury and disease outcomes both positively and negatively, as determined by specific signaling events and molecular effector mechanisms. 5, 7, 8 Taken together, observations from experimental animal studies indicate that the global inhibition or ablation of reactive astrogliosis is not likely to be a useful therapeutic approach and that in most situations it has the potential to do more harm than good. 5, 7, 8 Instead, therapeutic strategies should be directed at more specific astrocyte functions or at specific aspects of reactive astrogliosis, by targeting astrocyte-related molecular mechanisms. Considerable progress has been made in identifying the molecular mechanisms that regulate specific aspects of reactive astrogliosis or that are involved in mediating its functions and effects. 5, 7 Some of these molecules will be common to many cells (e.g., cytokines, ROS), whereas other molecules will be selective to astrocytes and may be targetable selectively (e.g., astrocyte glutamate transporters, SOD1).
In the sections that follow, we consider a number of molecules related to astrocytes and reactive astrogliosis and discuss their potential, and in some cases on-going development, as therapeutic targets for specific CNS disorders. Space constraints limit consideration to a crosssection of representative candidate molecules.
SPECIFIC POTENTIAL MOLECULAR THERAPEUTIC TARGETS RELATED TO ASTROCYTES AND REACTIVE ASTROGLIOSIS

Glutamate transmission and excitotoxicity
Astrocyte processes that envelope synapses express high levels of transporters for the amino acid neurotransmitter glutamate. These transporters clear the glutamate from the synaptic space; after uptake into astrocytes, the glutamate is converted by glutamine synthetase into glutamine and recycled back to synapses for reconversion to the active transmitter, glutamate. 30, 31 Through these transporters, astrocytes play essential roles in regulating extracellular levels of glutamate, which puts astrocytes in a position to reduce the potential for excitotoxicity. Indeed, genetic animal models have shown that loss of astrocytes or attenuation of astrocyte glutamate transporters such as EAAT1 and EAAT2 can lead to excitotoxic neurodegeneration. 12, 13 The expression or activity of astrocyte glutamate transporters is subject to a high degree of regulation both transcriptionally and post-transcriptionally. 30 -33 Gluta-mate transporter activity is reduced in various neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS). 34 Thus, modulation of EAAT1 and EAAT2 represents pharmacological targets that may modify neuronal function or protect neurons by manipulating glutamate levels. 9, 30 For example, augmenting the function of the astrocyte glutamate transporter EAAT2 with parawexin 1, a molecule isolated from spider venom, has been shown to protect retinal neurons from ischemic degeneration by enhancing glutamate uptake and thereby reducing the potential for glutamate excitotoxicity. 35, 36 A high-throughput screen of small molecules has identified that certain ␤-lactam antibiotics can enhance astrocyte-mediated glutamate uptake sufficiently to provide neuroprotection in models of stroke and ALS by stimulating the expression of astrocyte glutamate transporters and thereby reducing excitotoxicity. 37 In 2010, the ␤-lactam antibiotic ceftriaxone was in phase III clinical trials to determine efficacy in reducing excitotoxicity and neurodegeneration in ALS. Finally, a noncompetitive blocker of the AMPA glutamate receptor, talampanel, is also in clinical trials for ALS, with phase II just completed. 38 An additional potential target for manipulating astrocyte influences on glutamatergic synaptic transmission is astrocyte calcium signaling. Astrocytes exhibit transient elevations of cytosolic calcium levels in response to activation of a number of different membrane receptors; these calcium transients are regarded as a form of astrocyte excitability. 39 -41 Although the precise roles and mechanisms of astrocyte calcium signaling are incompletely understood, calcium transients in astrocytes have been shown to affect neuronal excitatory transmission, including network properties such as the ability to induce long-term potentiation. 42, 43 In this regard, it is particularly interesting that receptor selectivity has been noted, such that calcium transients triggered in astrocytes by activation of PAR-1 receptors led to the appearance of NMDA receptor-mediated slow inward currents in hippocampal pyramidal neurons, whereas calcium transients triggered in astrocytes by activation of P2Y1 receptors did not.
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Enzymes and scavengers related to oxidative stress NOS-2. Nitric oxide synthase-2 (NOS-2 or iNOS) is the inducible and calcium-independent isoform of NO synthase, the enzyme responsible for the production of the free radical NO. Whereas under normal physiological conditions NOS-2 is not expressed, it is induced due to injury or inflammation by a variety of stimuli, including interleukin 1␤ (IL-1␤), lipopolysaccharide (LPS), and tumor necrosis factor ␣ (TNF␣) in both astrocytes and microglia. [45] [46] [47] [48] [49] In several rodent models, there is evidence that NOS-2 expression or activity contributes to neurological injury and disease. 50 -56 For example, inhibition of NOS-2 activity 57 or genetic deletion of NOS-2 in mice subjected to a middle cerebral artery occlusion 53 have reduced infarct volumes, compared with wild-type controls. Furthermore, transgenic mice modeling Alzheimer's disease (i.e., hAPP-hPS1-double transgenic mice) were found to have reduced Alzheimer's disease-associated pathology when crossed with mice lacking NOS-2. 58 These mice exhibited reduced ␤-amyloid plaque formation, attenuated gliosis and notably had an increased lifespan, compared with that bred with NOS-2 ϩ/ϩ mice. 58 Other evidence suggests that NOS-2 induction may be beneficial in certain instances, 59 -62 including expression of astrocyte-specific NOS-2. 61, 62 In this regard, note that although one study found NOS-2 to contribute to Alzheimer's pathology in hAPP-hPS1-double transgenic mice, 58 different results were obtained when using a different transgenic mouse model of Alzheimer's disease, the Swedish familial double mutation APP (i.e., APPsw). When APPsw mice were crossed onto a NOS2 Ϫ/Ϫ background, the offspring exhibited increased Alzheimer's disease-associated pathology, including hyperphosphorylation of tau and increased levels of insoluble ␤-amyloid, along with an increase in neuronal degeneration, compared with APPsw mice on a NOS ϩ/ϩ background. 60 These observations suggest that NOS-2 may have positive and negative consequences in Alzheimer's disease, depending on the nature of the pathological etiologies.
Although the specific molecular mechanisms underlying the outcomes of NOS-2 induction in vivo remain largely elusive, several mechanisms have been established in vitro. It has been well-documented in a host of cells throughout the body that NOS-2-derived NO can contribute to cell death through the depletion of cellular energy sources by causing DNA strand breaks and by inhibiting mitochondrial respiration, among other mechanisms. 63, 64 Given the close apposition of astrocytes to the neuronal synapse, one putative role for an astrocytemediated effect of NOS-2-derived NO is in the modulation of neuronal glutamate activity. In support, astrocytespecific NOS-2-derived NO has been shown to enhance NMDA-dependent neuronal cell death through synaptic glutamate release. 46, 65, 66 At higher concentrations of NO, however, astrocytic NOS-2-derived NO may play a role in preventing excitotoxic cell death. In support, in astrocyte neuronal co-cultures addition of NO donors that released high concentrations of NO resulted in protection of NMDA-dependent excitotoxicity, an effect that was paralleled by a concentration-dependent reduction in NMDA channel activity. 61, 62 Given the intimate association of astrocyte end-feet with the vasculature and the known role of NO as a potent vasodilator, 67 astrocytic NOS-2-derived NO might be instrumental in increasing blood flow in times of need (e.g., by increasing oxygen extraction and in providing the proper energy sources needed during cellular repair).
Overall, evidence suggests that astrocyte-specific NOS-2 may be an important target for designing therapies for neurological diseases and disorders. Because NOS-2 can also be induced in microglia, it is critical that studies continue to elucidate the cell-type-specific regulation of NOS-2.
Cu/Zn superoxide dismutase (SOD). Mutations in Cu/Zn 2 superoxide dismutase (SOD) are the primary cause of familial ALS. Although, the precise mechanisms contributing to the disease are still unclear, numerous mechanisms, including oxidative stress and excitotoxicity, are thought to contribute to this disease. 68, 69 A large body of evidence suggests that astrocytes play an important role in the disease process. In a mouse model of ALS, reduced expression of dominantly inherited mutant SOD (G37R mutation) selectively in astrocytes of the brain through Cre-lox site-specific recombination resulted in delayed microglial activation and slowed late disease progression resulting in increased lifespan. 70 Notably, this implicated a sole molecule in astrocytes as mediating non-cell-autonomous neuropathology. Although the mechanism to explain how the decrease in astrocyte mutant SOD affects microglial reactivity and increases the survival of these mice is unknown, a robust reduction in astrocyte glutamate transporter GLT-1 expression was evident in both the motor cortex and spinal cord of ALS patients, 71 as well as in transgenic SOD-1 mutant mouse models. 72 Thus, devising therapies aimed at targeting mutant SOD in astrocytes may hold therapeutic promise for patients with inherited ALS. Along these lines, a transplantation-based replacement of astrocytes is reported to be neuroprotective in a mutant SOD1 transgenic mouse model of ALS. 73 Overall, these studies highlight the potential benefits that targeting astrocytes for therapeutic purposes, especially in ALS, may provide.
COX-2. The therapeutic potential, as well as preventative potential, of nonsteroidal anti-inflammatory inhibitory drugs (NSAIDs) in neurological diseases and disorders has been reviewed in great detail. 74 NSAIDs act to inhibit cyclooxygenases 1 and 2 (COX-1 and COX-2), enzymes that have various critical functions, through prostaglandin production, in regulating blood flow as well as inflammatory pathways. In addition, NSAIDS are now known to have additional targets, including NF-B, AP-1 and NOS among others (for review, see Lleo et al. 74 and Asanuma and Miyazaki 75 ). Treatment with NSAIDS in mouse models leads to diminished reactive astrogliosis, as evidenced after administration of ibuprofen in a transgenic model of Alzheimer's disease (APPV717I) 76 and of celecoxib in a transgenic model of ALS, 77 but it is not clear whether these are direct effects on astrocytes or indirect effects on other mechanisms that may in turn be responsible for astrocyte reactivity. In vitro studies have demonstrated that the NSAID acetylsalicylic acid abrogates both NF-B activity and the upregulation of glial fibrillary acidic protein (GFAP) induced by hypoxia in a human astroglial cell line. 78 Whether any of the beneficial effects of NSAIDs in vivo work directly through astrocytes, however, remains unclear and requires further investigation.
Glutathione. Astrocytes are the predominant source of glutathione (GSH) in the CNS, 79 and astrocyte-derived GSH plays important roles in protecting neurons from oxidative stress. 14, 15 Astrocyte GSH levels are influenced by cytokine signaling pathways associated with regulating specific aspects of astrogliosis; for example, disruption of STAT3 signaling in astrocytes markedly attenuates GSH levels and increases oxidative stress.
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S-nitrosoglutathione has been identified as a molecule produced by enteric astroglia that has mucosal barrier inducing functions. 80, 81 The roles of astroglial-derived S-nitrosoglutathione in the CNS have not yet been adequately explored. Modulating GSH production by reactive astrocytes is an interesting potential target for neuronal protection from oxidative stress in both acute and chronic CNS disorders.
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Cytokine and growth factor signaling Astrocytes can both secrete and respond to a number of important cytokines affecting the cellular state both of surrounding cells, such as microglia and neurons, and of astrocytes themselves. For example, cytokines such as IL-1␤, TNF␣, IL-6, and transforming growth factor-␤1 (TGF-␤1) can act to upregulate or downregulate other pro-and anti-inflammatory genes including NOS-2 and COX-2. 45, [82] [83] [84] [85] [86] Astrocytes also play a important role in the secretion of trophic factors such as glial cell linederived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and basic fibroblast growth factor (bFGF). Through the secretion of various growth factors, astrocytes can promote neuronal and oligodendrocyte survival, [87] [88] [89] [90] [91] as well as promote myelination in mature oligodendrocytes. 92 Thus, targeting the astrocyte in a way to promote growth factor release or to modulate cytokine release (up or down) is very much an important area of study. In this section, we will focus on some of the better characterized signaling pathways with respect to astrocytes and neurological diseases and disorders.
TGF-␤1 and SMAD3 signaling. Transforming growth factor-␤1 is a pleiotropic cytokine normally expressed at low to undetectable levels in the brain, but it is strongly upregulated under neuropathological conditions in a great variety of neurological diseases and disorders. [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] TGF-␤1 signals by binding to TGF␤RII, which then heterodimerizes and transphosphorylates the TGF␤ signaling receptor TGF␤RI, either activin-like kinase 5 or 1 (ALK5, ALK1), initiating an intracellular serine/threonine kinase signaling cascade. 110 Whereas ALK1 phosphorylates SMAD1/5/8, ALK5 phosphorylates SMAD2/3, each resulting in nuclear translocation of distinct signaling complexes producing disparate changes in gene expression. 110 The effects of TGF-␤1 in the brain are widespread and appear to be context-dependent with respect to the disease or disorder examined. An extensive literature has clearly demonstrated a neuroprotective role of TGF-␤1 in a variety of in vivo (i.e., middle cerebral artery occlusion) and in vitro (i.e., excitotoxic) models of cerebral ischemia. [111] [112] [113] [114] [115] [116] Other studies, however, show a proinflammatory and neuropathological role for TGF-␤1, which has been especially well documented in the case of Alzheimer's disease in both in vivo and in vitro rodent models. [117] [118] [119] [120] [121] [122] [123] Whether any of the roles of TGF-␤1 in neuroprotection or neuropathology rely on TGF-␤1 signaling through astrocytes remains elusive. However, TGF-␤1 is known to have several effects on astrocytes, including effects on gene expression, such as upregulation of amyloid precursor protein (APP), 120, 122, 124 modulation of the astrocyte response to pro-inflammatory mediators, 45, 82 and regulation of astrogliosis via increasing GFAP expression, eliciting hypertrophy, and facilitating glial scar formation through upregulation of extracellular matrix molecules (i.e., chondroitin sulfate proteoglycans, fibronectin, laminin). 119,124a Consistent with the effects of TGF-␤1 on extracellular matrix formation, mice that lack Smad3, the downstream effector of TGF-␤1 signaling through ALK5, exhibit a faster rate of wound closure after stab injury to the brain, compared with control mice. 125 Because all brain parenchymal cells are capable of secreting 126 and responding 107, [127] [128] [129] to TGF-␤1, it is interesting to note that neurons and endothelial cells are known to signal through both the ALK1 and ALK5 TGF␤RI receptors. 130, 131 To date, however, astrocytes and microglia are known to express and signal only through the ALK5 TGF␤RI. 132, 133 This difference in expression alone could prove to be fortuitous, but, in addition, microglia and astrocytes have, at least in part, divergent responses to the cytokine. For example, when NOS-2 is induced in cultured astrocytes upon pro-inflammatory stimulation, expression of NOS-2 and its resultant NO production are attenuated in microglia but are enhanced in astrocytes by TGF-␤1. 48, 82 Although progress has been made in understanding the differential cell-type response to TGF-␤1 in the brain, future elucidation of regulatory molecules in this pathway should prove to be fruitful.
NF-B signaling. The transcriptional induction of various inflammatory mediators such as IL-6 134 and NOS-2 requires that the transcription factor NF-B is activated, translocated into the nucleus, and bound to its cognate NF-B consensus element. NF-B can be activated by several pro-inflammatory mediators, including LPS, TNF␣ and IL-1␤. The classic endogenous activator, IL-1␤, is a cytokine that has been implicated in the pathogenesis of numerous neurological disorders, diseases, and injuries (for review, see Fogal and Hewett 135 ; for review of the global IL-1␤-mediated changes in astrocytes and the IL-1␤-specific signaling cascades in astrocytes, see John et al. 136 ). Because NF-B is not specific to astrocytes, identification of astrocyte-specific regulation is warranted. Inhibition of NF-B selectively in astrocytes is reported to ameliorate inflammation and to improve the rate of recovery after spinal cord injury. 137 Evidence suggests that chromatin remodeling may play a critical role in determining whether NF-B binds to a particular promoter in a given cell type. 138 -142 Given the cell-type-specific nature of epigenetic signatures, elucidation of the epigenetic modifications present in astrocytes will be important in understanding the transcriptional regulation of NF-B-dependent genes in astrocytes.
IL-6 and STAT3 signaling
Interleukin-6 is a cytokine that can be produced by both glia and neurons of the CNS and can be induced by inflammatory mediators, including IL-1␤, TNF␣, and LPS. 143 IL-6 signals through the gp130 receptor, which elicits activation of the JAK/Stat pathway and elicits changes in gene expression mainly through the activation of STAT3. 144 Interleukin-6 signaling through STAT3 is a known trigger of reactive astrogliosis. 7 The role of IL-6 can be beneficial or detrimental, depending on the rodent model (e.g., IL-6 overexpressor or IL-6 conditional overexpressor) used and the disease model studied. [145] [146] [147] [148] [149] With regard to astrocytes, STAT3 is an early trigger of astrogliosis. 150 Indeed, in a mouse model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced striatal degeneration, gp130-related cytokines (e.g., IL-6, ciliary neurotrophic factor) were upregulated prior to STAT3 activation in astrocytes (i.e., phosphorylated STAT3 [pSTAT3]) and nuclear translocation, events that preceded the upregulation of GFAP mRNA and protein expression. 150 Given that the Gfap promoter has STAT3 consensus binding sites known to be required for proper induction of GFAP, 151, 152 the notion of IL-6 signaling through STAT3 as a trigger of astrogliosis, which is hallmarked by an upregulation in GFAP expression, is not surprising. However, not only is STAT3 a trigger of astrogliosis, but it seems to be required for proper astrogliosis to occur, at least in the case of spinal cord injury. 153 More specifically, astrocyte-specific Stat3 conditional knockout mice have attenuated GFAP expression, diminished astrocyte hypertrophy, and a lack of proper glial scar formation, compared with Stat3 ϩ/ϩ mice. This genetic deletion of Stat3 selectively in astrocytes also resulted in non-cell-autonomous effects, including increased microgliosis and inflammatory cell infiltration, which corresponded to an increase in lesion size following spinal cord injury and resulted in a diminution in motor function recovery. 153 A recently published study found that triptolide, an active ingredient in the traditional Chinese herb Tripterygium wilfordii Hook. f., was found to reduce astrogliosis in vitro and in vivo. 154 In both cases, in an astrocyte culture scratch injury model and after spinal cord injury in rat, pSTAT3 levels were reduced in parallel with a decrease in GFAP immunoreactivity. In culture, a decreased number of proliferative cells were present, whereas in vivo a marked reduction in glial scar formation as assessed 4 weeks post-injury was observed. In addition, animals treated with triptolide have improved locomotion function, compared with control spinal cordinjured mice. 154 However, given that triptolide can affect other cells in an anti-inflammatory fashion, including microglia, 155 whether the in vivo phenotype of diminished astrogliosis is directly or indirectly mediated by the herb remains unknown. Overall, further study of IL-6 and STAT3 signaling pathways should prove beneficial in the long term.
Other cytokines and growth factors. Astrocytes can express receptors and respond to a large variety of other growth factors and cytokines, including but by no means limited to TNF␣, EGF, FGF, endothelins, and various interleukins (for reviews, see Sofroniew 7 and Mena and García de Yébenes 91 ). These factors can induce the expression of molecules associated with reactive astrogliosis, such as GFAP, or have been implicated in astrocyte proliferation. 156, 157 Space constraints limit detailed consideration here, but some of these factors may come to represent interesting potential therapeutic targets.
Nucleotides and their receptors
In addition to their many essential intracellular functions, the nucleotides ATP, ADP, and adenosine have functions as extracellular signaling molecules that act through specific plasma membrane receptors, the purinoceptors P2X and P2Y and the adenosine receptor (A), all of which have multiple family members. 158 ATP signaling triggers elevations in cytosolic calcium in astrocytes 44, 159, 160 and leads to gene expression changes associated with reactive astrogliosis after trauma-induced cell injury in vitro. [161] [162] [163] The molecular pharmacology of P2X, P2Y, and adenosine involves a number of inhibitors and activators, and some of these are being studied for effects on reactive astrogliosis and CNS injury and repair after traumatic injuries such as spinal cord injury. 164, 165 This is a promising area for future exploration.
Epigenetic regulators
Epigenetic regulation of gene expression and its role in neurological diseases and disorders is a growing field of potential therapeutic importance. See Urdinguio et al. 166 for a thorough and recent review of the epigenetic regulation in relation to neurological diseases and disorders. Two putative targets of regulation have been widely studied in recent years, namely histone deacetylases (HDACs) and histone acetyltransferases (HATs). These HATs and HDACs have opposing roles in the acetylation and deacetylation of histones, a dynamic process that can robustly and globally affect gene expression patterns in a cell. 166a HATs and HDACs not only affect histone acetylation patterns, but can modulate transcription factors through acetylation. Moreover, the patterns of genes affected by this process vary among cell types and are context-dependent. Thus, modulation of HAT and HDAC function through pharmacological manipulation could broadly influence astrocyte responses to other signaling molecules and could powerfully modulate astrocyte functions in health and disease.
HDAC inhibitors.
Pharmacological inhibition of HDACs results in both an increase in histone acetylation and a decrease in neuropathology and neurological deficits in a variety of animal models of neurological diseases and disorders, including experimental autoimmune encephalomyelitis 167 and ischemia. 168 -171 Although the exact cellular and molecular targets underlying such beneficial effects of HDAC inhibitors remain unknown, in vivo and in vitro evidence suggests that astrocytes may be important targets. 171 Astrocytes express various HDACs, and treatment of rodent astrocytes in vitro with HDAC inhibitors, including valproic acid and trichostatin A, results in global and specific histone residue hyperacetylation 172 and thus changes in gene expression profiles. In astrocytes, several genes have already been shown to be affected by various HDAC inhibitors including the reduction in levels of various pro-inflammatory-related genes, 173 the upregulation of the glutamate transporter GLT-1 174, 175 and the enhancement of growth factor secretion (i.e., GDNF and BDNF). 171 The HDAC inhibitor valproic acid is currently used in treating epilepsy 176 and is also being tested for cancer. 177 For further review on the potential of HDAC inhibitors as therapies in neurological diseases and disorders, see Langley et al. 178 and Kazantsev and Thompson.
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The HAT inhibitor curcumin. Curcumin, a major curcuminoid in the spice turmeric, is an inhibitor of the histone acetyltransferase (HAT) p300 180, 181 ; it is currently being investigated in rodent models of neurological disease as a prospective therapeutic option. The effects of curcumin have been generally described as having anti-inflammatory and antioxidant properties. Consistent with that, evidence suggests that curcumin reduces clinical severity or improves neurological function in several neurological diseases and disorders and injuries, including experimental allergic encephalomyelitis 182 and traumatic brain injury (TBI) 183 in mice and spinal cord injury in rat. 184 Pathologically, curcumintreated animals subjected to contusional brain injury exhibit reduced edema correlating with a reduction in levels of IL-1␤ and aquaporin 4 (AQP4), compared with control animals. 183 Although it is unclear what underlies the beneficial effect of curcumin in these instances, it is clear that curcumin affects astrocytes. In mouse models of autoimmune encephalomyelitis, 182 spinal cord injury, 184 and traumatic brain injury, 183 curcumin-treated animals exhibit reduced astrogliosis, as evidenced by an attenuation in the upregulation of GFAP expression, an effect that appears to be cell-autonomous, in that curcumin also reduces GFAP expression in purified astrocyte cultures. 184 Treatment of mouse cortical astrocytes with curcumin in vitro also reduces the IL-1␤-mediated activation of the classic inflammatory mediator NF-B.
183 Future studies delineating the roles of curcumin under neuropathological conditions and in the regulation of signaling pathways and gene expression profiles in astrocytes should be worthwhile.
Other astrocyte-specific molecules and regulators Aquaporin 4. A water channel protein responsible for bidirectionally transporting water to and from the blood and the brain, AQP4 is normally localized on astrocyte end-feet. The expression levels and localization of AQP4 in astrocytes are subject to much regulation. During inflammatory conditions, for example, AQP4 is subject to upregulation by cytokines such as IL-1␤. 183 Dysregulation of AQP4 expression or function can lead to brain edema. 185, 186 Mice lacking Aqp4 exhibit decreased brain edema that corresponds to a decrease in astrocyte end-feet swelling following cerebral ischemia or acute water intoxication.
185 AQP4 expression is elevated in animal models of hydrocephalus, an effect that seems to be productive, given that both edema clearance and survival are decreased in mice that lack Aqp4. 187 Given the large number of known regulators for AQP4, including arginine-vasopressin, which can activate AQP4-mediated radial water transport across the astrocyte syncytium, 188 it will be important to continue to study the regulation of AQP4 and to test whether manipulation of this channel proves useful in the treatment of various diseases involving brain edema. For review of AQP4 function in astrocytes in greater detail, see Seifert et al. 4 and Nag et al. 189 It is also important to note that AQP4 is now established as the target antigen in the CNS autoimmune demyelinating inflammatory disorder neuromyelitis optica. 190, 191 Neuropathological evaluations in neuromyelitis optica are consistent with a mechanism whereby autoimmune destruction of astrocytes triggered by binding of AQP4 autoantibodies leads to inflammatory cell invasion and destruction of neural parenchyma. [192] [193] [194] These neuropathological findings are in line with and are supported by a large body of work in experimental animals showing that astrocytes are essential regulators that restrict inflammatory cell infiltration into CNS parenchyma and protect neural tissue during both innate and adaptive immune inflammation. 7, 13, 23, 194, 195 Interventions that reduce autoimmune recognition of AQP4 and thereby reduce consequent astrocyte dysfunction and damage represent important therapeutic targets.
Connexin gap junctions. Astrocytes are highly connected to one another by homologous connexin 43 (Cx43) gap junctional coupling, forming what is known as the glial syncytium, in which interglial communication (e.g., Ca 2ϩ waves) can occur. 196 -199 This glial network afforded by Cx43 gap junctions is important not only in supporting neuronal activity by sustaining proper energy sources, but also in orchestrating neuronal network activity through the release of gliotransmitters such as L-glutamate in an apposing glial syncytium. 200 Under neuropathological conditions, there is a shift in either Cx43 expression or in cellular localization (or both), and glial communication through the syncytium is stunted. 201 This change in astrocyte coupling can be either beneficial or detrimental, an effect that is likely diseaseand context-dependent. Nevertheless, astrocyte Cx43 will likely be a good target to consider modulating, with the goal of ameliorating the neuropathology in specific instances or contexts of neurological diseases and disorders. For extensive review on this topic, see Giaume et al. 200 and Kielian.
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Potassium channels. The role of astrocyte inwardly rectifying K ϩ channels (K ir channels) with regard to brain function has been nicely and thoroughly reviewed. 203 In brief, K ir channels are localized to astrocyte end-feet and are responsible for maintaining the resting membrane potential of astrocytes, needed for proper K ϩ buffering. 203 Given that the predominant astrocyte K ir channel K ir 4.1 is highly regulated, and that its expression or activity (or both) decrease upon injury, inflammation, or disease, it seems reasonable to attempt to enhance its activity or expression as a potential therapeutic target.
Arundic acid. Although the precise molecular target or targets of arundic acid (ONO-2506) remain elusive, it is reported to target changes in astrocyte gene expression while also ameliorating several neurological diseases and disorders in rodent models. Notably, in vitro, the neuroprotective effect of arundic acid on neurons in culture required the presence of astrocytes. In vivo, astrogliosis as measured via GFAP immunoreactiv-ity is reduced by arundic acid in a mouse model of Alzheimer's disease (APP sw transgenic mice), 204 as well as in mice subjected to MPTP-mediated neurotoxicity. 205 Notably, treatment with arundic acid resulted in amelioration of the pathology associated with the aforementioned mouse model 204, 205 and in mice subjected to a permanent focal ischemia. 206 Although the mechanism or mechanisms for these beneficial effects remain unknown, studies have speculated that they may involve astrocyte-specific functions, including modulation of glutamate transporter (increased) and S-100B (decreased) expression. More research will be necessary to fully elucidate whether this compound does target astrocytes and, if so, what molecular mechanisms might be involved.
CELL DELIVERY
It deserves brief mention that transplantation strategies involving astrocytes are also under investigation. For example, grafts of stem or progenitor cells that mature into healthy astrocytes are reported to improve outcome in a mouse model of ALS in which host astrocytes are abnormal and express a mutant SOD. 73 A different strategy uses grafts of astrocytes that are genetically modified to produce specific molecules, such as growth factors, as therapeutic pumps to deliver those molecules in specific locations. 207, 208 Such grafts of genetically modified astrocytes may be able to provide long-term, locally restricted delivery of therapeutic molecules via cells that integrate into the neural parenchyma both structurally and functionally.
CONCLUSION
Reactive astrogliosis is emerging as a complex and multifaceted process that can range from subtle and reversible alterations in gene expression and morphology to the pronounced and long-lasting changes associated with scar formation. The responses of reactive astrocytes to CNS insults are controlled in a context-dependent manner by specific signaling mechanisms that mediate numerous essential beneficial functions, but under certain circumstances can lead to harmful effects. The simplistic but widely held notions that reactive astrogliosis and scar formation are maladaptive responses and that complete blockade of reactive astrogliosis per se will be beneficial, are no longer tenable. Big-picture functions of reactive astrogliosis and scar formation include protecting neural cells, tissue and function, and restricting the spread of inflammation and infection. Dysfunctions of reactive astrogliosis and scar formation have the potential to contribute to, or to be primary causes of, CNS disease mechanisms, either through loss of normal functions or through gain of detrimental effects. Accordingly, therapeutic strategies will need to be directed at specific aspects of reactive astrogliosis and specific molecular mechanisms that may be augmented or attenuated for specific purposes. In this regard, it will be important to elucidate the many potential biological functions of specific molecules, including potential cross-talk between different cellular signaling and other pathways. Even well thought-out therapeutic targets could have unexpected ill-effects, which highlights the need to further unravel the basic science underlying potential therapeutic targets.
